Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Assets Average over the past 12 years, most recently at $738.3 million for Q4 2025.

  • Quarterly results put Assets Average at $738.3 million for Q4 2025, down 2.49% from a year ago — trailing twelve months through Dec 2025 was $738.3 million (down 2.49% YoY), and the annual figure for FY2025 was $820.9 million, up 33.18%.
  • Assets Average for Q4 2025 was $738.3 million at Viridian Therapeutics, Inc.\DE, up from $579.7 million in the prior quarter.
  • Over the last five years, Assets Average for VRDN hit a ceiling of $757.2 million in Q4 2024 and a floor of $120.5 million in Q2 2021.
  • Median Assets Average over the past 5 years was $410.2 million (2023), compared with a mean of $425.9 million.
  • Biggest five-year swings in Assets Average: soared 411.79% in 2021 and later fell 14.59% in 2025.
  • Viridian Therapeutics, Inc.\DE's Assets Average stood at $212.5 million in 2021, then soared by 106.08% to $437.8 million in 2022, then dropped by 6.45% to $409.6 million in 2023, then soared by 84.86% to $757.2 million in 2024, then dropped by 2.49% to $738.3 million in 2025.
  • The last three reported values for Assets Average were $738.3 million (Q4 2025), $579.7 million (Q3 2025), and $621.7 million (Q2 2025) per Business Quant data.